<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dig Dis Sci</journal-id><journal-id journal-id-type="iso-abbrev">Dig. Dis. Sci</journal-id><journal-title-group><journal-title>Digestive Diseases and Sciences</journal-title></journal-title-group><issn pub-type="ppub">0163-2116</issn><issn pub-type="epub">1573-2568</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28589238</article-id><article-id pub-id-type="pmc">5561162</article-id><article-id pub-id-type="publisher-id">4598</article-id><article-id pub-id-type="doi">10.1007/s10620-017-4598-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Pimentel</surname><given-names>M.</given-names></name><address><phone>(310) 423-6143</phone><email>Mark.Pimentel@cshs.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cash</surname><given-names>B. D.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lembo</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wolf</surname><given-names>R. A.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Israel</surname><given-names>R. J.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Schoenfeld</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2152 9905</institution-id><institution-id institution-id-type="GRID">grid.50956.3f</institution-id><institution>GI Motility Program, Division of Gastroenterology, </institution><institution>Cedars-Sinai Medical Center, </institution></institution-wrap>8730 Alden Drive, Suite 225E, Los Angeles, CA 90048 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9552 1255</institution-id><institution-id institution-id-type="GRID">grid.267153.4</institution-id><institution>Division of Gastroenterology, </institution><institution>University of South Alabama, </institution></institution-wrap>6000 University Commons, 75 University Blvd, S, Mobile, AL 36688 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9011 8547</institution-id><institution-id institution-id-type="GRID">grid.239395.7</institution-id><institution>Beth Israel Deaconess Medical Center, </institution></institution-wrap>330 Brookline Avenue, Boston, MA 02215 USA </aff><aff id="Aff4"><label>4</label>400 Somerset Corporate Blvd., Bridgewater, NJ 08807 USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0419 7787</institution-id><institution-id institution-id-type="GRID">grid.414723.7</institution-id><institution>Gastroenterology and Hepatology Division, </institution><institution>John D. Dingell VA Medical Center, </institution></institution-wrap>4646 John R Street, Detroit, MI 48201 USA </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>62</volume><issue>9</issue><fpage>2455</fpage><lpage>2463</lpage><history><date date-type="received"><day>2</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>29</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; Springer Science+Business Media New York 2017</copyright-statement></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Rifaximin has demonstrated efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D).</p></sec><sec><title>Aim</title><p id="Par2">To determine the rifaximin repeat treatment effect on fecal bacterial antibiotic susceptibility.</p></sec><sec><title>Methods</title><p id="Par3">Patients with IBS in Trial 3 (TARGET 3) study who responded to open-label rifaximin 550&#x000a0;mg three times daily for 2&#x000a0;weeks, with symptom recurrence within 18&#x000a0;weeks, were randomized to double-blind treatment: two 2-week repeat courses of rifaximin or placebo, separated by 10&#x000a0;weeks. Prospective stool sample collection occurred before and after open-label rifaximin, before and after the first repeat course, and at the end of the study. Susceptibility testing was performed with 11 antibiotics, including rifaximin and rifampin, using broth microdilution or agar dilution methods.</p></sec><sec><title>Results</title><p id="Par4">Of 103 patients receiving open-label rifaximin, 73 received double-blind rifaximin (<italic>n</italic>&#x000a0;=&#x000a0;37) or placebo (<italic>n</italic>&#x000a0;=&#x000a0;36). A total of 1429 bacterial and yeast isolates were identified, of which Bacteroidaceae (36.7%) and Enterobacteriaceae (33.9%) were the most common. In the double-blind phase, <italic>Clostridium difficile</italic> was highly susceptible to rifaximin [minimum inhibitory concentration (MIC) range 0.008&#x02013;1&#x000a0;&#x000b5;g/mL] and rifampin (MIC range 0.004&#x02013;0.25&#x000a0;&#x000b5;g/mL). Following double-blind rifaximin treatment, <italic>Staphylococcus</italic> isolates remained susceptible to rifaximin at all visits (MIC<sub>50</sub> range &#x02264;0.06&#x02013;32&#x000a0;&#x000b5;g/mL). Rifaximin exposure was not associated with long-term cross-resistance of Bacteroidaceae, Enterobacteriaceae, and Enterococcaceae to rifampin or nonrifamycin antibiotics tested.</p></sec><sec><title>Conclusions</title><p id="Par5">In this study, short-term repeat treatment with rifaximin has no apparent long-term effect on stool microbial susceptibility to rifaximin, rifampin, and nonrifamycin antibiotics.</p></sec><sec><title>ClinicalTrials.gov Identifier</title><p id="Par6">NCT01543178.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s10620-017-4598-7) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Irritable bowel syndrome</kwd><kwd>Diarrhea</kwd><kwd>Microbiology</kwd><kwd>Rifaximin</kwd></kwd-group><funding-group><award-group><funding-source><institution>Salix Pharmaceuticals</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par7">Irritable bowel syndrome (IBS) is a chronic, recurrent functional bowel disorder characterized by abdominal pain with alterations in bowel habit [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Subtypes of IBS are characterized by stool pattern and include diarrhea-predominant IBS (IBS-D), constipation-predominant IBS, and mixed IBS [<xref ref-type="bibr" rid="CR1">1</xref>]. The etiology of IBS remains to be fully elucidated; however, IBS is considered a multifactorial condition that is affected by both host (e.g., alterations in gut motility and/or gut microbiota) and environmental factors (e.g., diet) [<xref ref-type="bibr" rid="CR2">2</xref>]. Indeed, the gut microbiota of patients with IBS-D differ both quantitatively and qualitatively from those of healthy individuals [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. Antibiotics (e.g., rifaximin, neomycin) have been shown to improve symptoms of IBS [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. However, administration of systemic antibiotics may be limited in IBS because of the potential for the development of bacterial antibiotic resistance and adverse events and because of the increased risk of <italic>Clostridium difficile</italic> infection [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par8">Rifaximin is an oral nonsystemic gastrointestinal-targeted antibiotic with broad-spectrum activity in vitro against Gram-negative and Gram-positive aerobic and anaerobic bacteria, including <italic>C. difficile</italic> [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Rifaximin binds the &#x003b2; subunit of DNA-dependent RNA polymerase of target bacteria, inhibiting the synthesis of bacterial RNA [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Rifaximin has demonstrated efficacy and safety in the treatment of IBS-D and was approved in 2015 by the US Food and Drug Administration for the treatment of IBS-D in adults [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. In two phase 3 identically designed, randomized, double-blind studies [Trial 1 and 2 (TARGET 1 and 2)], a significantly greater percentage of patients with IBS-D receiving rifaximin 550&#x000a0;mg three times daily for 14&#x000a0;days reported adequate relief of global IBS symptoms for &#x02265;2 of the first 4&#x000a0;weeks post-treatment compared with patients receiving placebo (pooled data: 40.7 vs. 31.7%, respectively; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) [<xref ref-type="bibr" rid="CR17">17</xref>]. In a double-blind study evaluating the efficacy and safety of repeat treatment with rifaximin [Trial 3 (TARGET 3)], patients who experienced symptom relapse within 18&#x000a0;weeks of observation after initial response (&#x02265;30% decrease from baseline in mean weekly pain score and &#x02265;50% decrease from baseline in number of days/week with Bristol Stool Scale type 6 or 7 stool for &#x02265;2 of first 4&#x000a0;weeks post-treatment) to open-label rifaximin 550&#x000a0;mg three times a day for 2&#x000a0;weeks were randomized to receive repeat treatments of rifaximin 550&#x000a0;mg three times a day or placebo for 14&#x000a0;days. The percentage of responders to repeat treatment was significantly greater with rifaximin than with placebo (38.1 vs. 31.5%, <italic>P</italic>&#x000a0;=&#x000a0;0.03) [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par9">The safety profile of rifaximin was generally comparable to that of placebo according to the results of a pooled safety analysis of patients with nonconstipation forms of IBS participating in a phase 2 study and Trial 1 and 2 (<italic>n</italic>&#x000a0;=&#x000a0;1932) [<xref ref-type="bibr" rid="CR22">22</xref>]. No patients in the pooled population developed <italic>C. difficile</italic> colitis during dosing. The risk of bacteria developing resistance with rifaximin is thought to be low [<xref ref-type="bibr" rid="CR10">10</xref>], possibly because of the minimal systemic absorption of rifaximin [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], the requirement of a stable mutation in host cell DNA (in contrast with plasmid-based mechanisms) [<xref ref-type="bibr" rid="CR25">25</xref>], and the inability of resistant bacteria to effectively colonize the gastrointestinal tract [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Mutations associated with rifaximin resistance following exposure to high concentrations of rifaximin have been shown to occur in approximately 1.0&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;8</sup> to 2.6&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;6</sup> bacteria, with some variation among bacterial species [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The aim of this substudy was to examine the susceptibility of stool bacteria to select antibiotics, including rifaximin and rifampin, isolated from a subgroup of patients with IBS-D who participated in Trial 3.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study Design and Patients</title><p id="Par10">The patient population and the study design of Trial 3 (TARGET 3) have been described previously [<xref ref-type="bibr" rid="CR21">21</xref>]. Briefly, Trial 3 was a randomized, double-blind, placebo-controlled phase 3 study (ClinicalTrials.gov identifier NCT01543178). Patients aged &#x02265;18&#x000a0;years were eligible to participate if they had a diagnosis of IBS (based on Rome III criteria) and did not experience adequate relief of global IBS symptoms and bloating during a placebo screening phase. Patients were excluded if (after beginning diary assessments) they were taking probiotics or taking rifaximin or any other antibiotic 14&#x000a0;days prior to providing written informed consent [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par11">Patients received open-label rifaximin 550&#x000a0;mg three times daily for 2&#x000a0;weeks, followed by a 4-week treatment-free follow-up to assess response (improvement in abdominal pain due to IBS (&#x02265;30% reduction from baseline in mean weekly pain score) and stool consistency (&#x02265;50% reduction from baseline in number of days/week with Bristol Stool Scale type 6 or 7 stool) during &#x02265;2 of the first 4&#x000a0;weeks post-treatment) [<xref ref-type="bibr" rid="CR21">21</xref>]. Responders continued in the study (nonresponders were withdrawn from further participation) and were monitored during a treatment-free observation phase of up to 18&#x000a0;weeks to determine IBS symptom recurrence (defined as loss of treatment response for either weekly abdominal pain or stool consistency for &#x02265;3&#x000a0;weeks of a consecutive, rolling 4-week period during the 18-week observation phase). Patients with recurrence were randomly assigned (1:1), in a double-blind manner, to two repeat 2-week courses of treatment with rifaximin 550&#x000a0;mg or placebo three times daily, with the two repeat phases separated by 10&#x000a0;weeks. All patients provided written informed consent [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec4"><title>Collection of Stool Samples</title><p id="Par12">All patients participating in Trial 3 also consented to provide stool samples. For inclusion in the current substudy, patients were selected using random number generator statistical software. Patients were selected in a manner to incorporate both responders and nonresponders. Prospective fecal culture and susceptibility testing were conducted with stool samples collected from patients prior to (open-label baseline) and after open-label treatment with rifaximin (open-label week 2), and prior to (double-blind baseline) and after the first double-blind course (double-blind week 2), and at the end of the study. Fresh stool samples were collected from patients at study visits when possible; patients who could not provide a fresh stool sample received a stool collection kit for home use with instruction to refrigerate the sample immediately and to deliver it to the clinic as soon as possible. At the clinic, stool samples were divided into 2-mL aliquots in polypropylene cryovials and stored at &#x02264;&#x02212;20&#x000a0;&#x000b0;C; samples were then shipped on dry ice for long-term storage at &#x02264;&#x02212;70&#x000a0;&#x000b0;C.</p><p id="Par13">Bacteria were isolated from stool by inoculation on tryptic soy agar plates with 5% sheep&#x02019;s blood to identify aerobic bacteria; the anaerobes <italic>C. difficile</italic> and <italic>Bacteroides</italic> species were isolated by inoculation of stool samples onto cycloserine cefoxitin fructose agar or <italic>Bacteroides</italic> bile esculin agar, respectively. Identification of bacteria was achieved by morphology, Gram staining, other tests (catalase, hemolysis), and molecular identification as necessary. The presence of yeast was confirmed by wet mount, and yeast species were identified by the Vitek<sup>&#x000ae;</sup> 2 System (bioM&#x000e9;rieux, Inc., Durham, NC, USA); susceptibility testing was not performed on yeast isolates.</p></sec><sec id="Sec5"><title>Susceptibility Testing</title><p id="Par14">Bacteria tested for antibiotic susceptibility were from the genera <italic>Bacteroides, Citrobacter, Clostridium, Enterobacter, Enterococcus, Escherichia, Klebsiella, Pseudomonas, Serratia,</italic> and <italic>Staphylococcus</italic>. Susceptibility testing was performed with 11 antibiotics using either the broth microdilution method (aerobic bacteria) or the agar dilution method (anaerobic bacteria). Aerobic bacteria were tested with rifaximin, rifampin, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, meropenem, and piperacillin/tazobactam. Anaerobic bacteria were tested with rifaximin, rifampin, fidaxomicin, metronidazole, and vancomycin.</p></sec><sec id="Sec6"><title>Data Analysis</title><p id="Par15">Each bacterial species isolated and tested was grouped into a family [i.e., Bacteroidaceae, Clostridiaceae, Enterobacteriaceae (including <italic>Escherichia, Klebsiella, Proteus, Enterobacter,</italic> and <italic>Citrobacter</italic> species), Enterococcaceae, Pseudomonadaceae, or Staphylococcaceae]. The minimum inhibitory concentration (MIC) at which &#x02265;50% of isolates were inhibited was the MIC<sub>50</sub> for the population, and the MIC at which &#x02265;90% of isolates were inhibited was the MIC<sub>90</sub> for the population. Clinical and Laboratory Standards Institute (CLSI) break points for each species were used to interpret MIC data [<xref ref-type="bibr" rid="CR29">29</xref>]. For antibiotics with defined susceptible and intermediate categories, the susceptible classification was used for these analyses. For antibiotics without established CLSI break points, ranges for in vitro sensitivity were used if provided on the package insert. In all other cases (i.e., antibiotics without CLSI defined break points, in vitro susceptibility not provided on package insert), MIC values at or above the highest dilution tested in the MIC panel were considered resistant, and MIC values below the highest dilution were considered susceptible. The follow-up period was variable; therefore, for purposes of data analysis, the follow-up visits were combined into 4-week periods.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patient Population</title><p id="Par16">A total of 103 patients were randomly selected for inclusion in the stool microbiota substudy; this was a subgroup of patients included in the Trial 3 study [<xref ref-type="bibr" rid="CR21">21</xref>]. Patients were mostly white (82.5%), mostly female (73.8%), had a mean age of 47.9&#x000a0;years (range 19&#x02013;85&#x000a0;years), and had a baseline average of 3.5 daily bowel movements. Of the 103 patients who received open-label rifaximin, 73 also participated in the double-blind phase (rifaximin, <italic>n</italic>&#x000a0;=&#x000a0;37; placebo, <italic>n</italic>&#x000a0;=&#x000a0;36). In the double-blind phase, a similar percentage of patients in the rifaximin and placebo groups, respectively, were female (70.3 and 72.2%) and had a similar frequency of daily bowel movements (3.1 and 2.9). Patients in the rifaximin and placebo groups had similar mean ages, respectively, of 46.9&#x000a0;years (range 22&#x02013;85&#x000a0;years), and 47.7&#x000a0;years (range 19&#x02013;74&#x000a0;years); however, the percentage of white patients was lower in the rifaximin group (75.7%) than in the placebo group (88.9%).</p><p id="Par17">A total of 1429 bacterial and yeast isolates were identified from stool samples; the most common isolates were members of the families Bacteroidaceae (525 [36.7%]) and Enterobacteriaceae (484 [33.9%]; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). A small number of Clostridiaceae (22 [1.5%]) and Pseudomonadaceae (4 [0.3%]) isolates were cultured. A total of 17 yeast isolates from 14 patients were identified (1.2%).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Most abundant isolates from stool cultures (<italic>N</italic>&#x000a0;=&#x000a0;1429)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Bacteria family</th><th align="left">Counts</th><th align="left">Percentage of total</th></tr></thead><tbody><tr><td align="left">Bacteroidaceae</td><td char="." align="char">525</td><td char="." align="char">36.7</td></tr><tr><td align="left">&#x000a0;<italic>Bacteroides vulgatus</italic>
</td><td char="." align="char">178</td><td char="." align="char">12.5</td></tr><tr><td align="left">&#x000a0;<italic>Bacteroides ovatus</italic>
</td><td char="." align="char">114</td><td char="." align="char">8.0</td></tr><tr><td align="left">&#x000a0;<italic>Bacteroides fragilis</italic>
</td><td char="." align="char">102</td><td char="." align="char">7.1</td></tr><tr><td align="left">Enterobacteriaceae</td><td char="." align="char">484</td><td char="." align="char">33.9</td></tr><tr><td align="left">&#x000a0;<italic>Escherichia coli</italic>
</td><td char="." align="char">337</td><td char="." align="char">23.6</td></tr><tr><td align="left">&#x000a0;<italic>Klebsiella pneumoniae</italic>
</td><td char="." align="char">72</td><td char="." align="char">5.0</td></tr><tr><td align="left">Enterococcaceae</td><td char="." align="char">286</td><td char="." align="char">20.0</td></tr><tr><td align="left">&#x000a0;<italic>Enterococcus faecalis</italic>
</td><td char="." align="char">117</td><td char="." align="char">8.2</td></tr><tr><td align="left">&#x000a0;<italic>Enterococcus faecium</italic>
</td><td char="." align="char">90</td><td char="." align="char">6.3</td></tr><tr><td align="left">Staphylococcaceae</td><td char="." align="char">91</td><td char="." align="char">6.4</td></tr><tr><td align="left">&#x000a0;<italic>Staphylococcus aureus</italic>
</td><td char="." align="char">25</td><td char="." align="char">1.7</td></tr></tbody></table><table-wrap-foot><p>Species presented in table do not represent all isolates that were cultured from stool. The isolates included in the table represent bacterial families that are &#x02265;5% of the total number of isolates and bacteria of clinical importance</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>Rifaximin and Rifampin Susceptibility</title><sec id="Sec10"><title>Open-Label Phase</title><p id="Par18">In the open-label phase, 366 <italic>Bacteroides</italic> isolates were identified (Table S1). The range of MIC values for rifaximin and rifampin was wide at each visit and across visits. The MIC<sub>50</sub> and MIC<sub>90</sub> values for rifaximin increased from baseline, although susceptible isolates were still observed at week 2 and weeks 7&#x02013;32. The MIC<sub>50</sub> values for rifampin increased from baseline to week 2 and remained high through week 23, when the MIC<sub>50</sub> value returned to the baseline level.</p><p id="Par19">A total of 14 <italic>C. difficile</italic> isolates were identified; all isolates were highly susceptible to rifaximin (MIC range 0.008&#x02013;0.12&#x000a0;&#x000b5;g/mL) across visits. Similarly, most <italic>C. difficile</italic> isolates (<italic>n</italic>&#x000a0;=&#x000a0;14) were highly susceptible to rifampin (MIC range 0.002&#x02013;0.015&#x000a0;&#x000b5;g/mL) across all visits, with one exception. The <italic>C. difficile</italic> isolate from one patient had a MIC of 16&#x000a0;&#x000b5;g/mL at week &#x02265;23; however, this isolate was sensitive to all other antibiotics tested, including rifaximin.</p><p id="Par20">A total of 328 Enterobacteriaceae isolates were identified (Table S2). MIC<sub>50</sub> and MIC<sub>90</sub> values for rifaximin increased from baseline to week 2 and remained higher until weeks 19&#x02013;22, when MIC<sub>50</sub> and MIC<sub>90</sub> values decreased for the rest of the study. The baseline rifampin MIC range increased to a maximum MIC at week 2.</p><p id="Par21">In addition, susceptibility of Enterococcaceae to rifaximin was consistent throughout the open-label phase (Table S3). Only three <italic>Pseudomonas</italic> isolates were identified in the open-label phase of the study, all in the follow-up period. Staphylococcaceae isolates were highly susceptible to rifaximin and rifampin at baseline; at week 2, the rifaximin and rifampin MIC<sub>50</sub> and MIC<sub>90</sub> values increased (Table S4). Rifaximin MIC<sub>50</sub> levels recovered to baseline levels at week 7; MIC<sub>90</sub> levels recovered to baseline levels at week 23.</p></sec><sec id="Sec11"><title>Double-Blind Phase</title><p id="Par22">A total of 107 and 129 <italic>Bacteroides</italic> isolates were identified for rifaximin susceptibility testing in samples from patients receiving double-blind rifaximin or placebo, respectively; 121 and 129 <italic>Bacteroides</italic> isolates were identified for rifampin susceptibility testing in samples from patients receiving double-blind rifaximin or placebo, respectively. <italic>Bacteroides</italic> isolates demonstrated a wide range of susceptibility to rifaximin and rifampin for both the double-blind rifaximin and placebo groups, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). There were no apparent differences in susceptibility of <italic>Bacteroides</italic> to rifaximin or rifampin in the double-blind rifaximin or placebo groups. Rifaximin MIC<sub>50</sub> values decreased compared with baseline at week &#x02265;23 following double-blind rifaximin or placebo treatment.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Susceptibility of Bacteroidaceae to rifaximin or rifampin in the double-blind phase of the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Timepoint<sup>a</sup> (patients)</th><th align="left" colspan="4">Rifaximin</th><th align="left" colspan="4">Rifampin</th></tr><tr><th align="left">Isolates (<italic>n</italic>)</th><th align="left">MIC range (&#x000b5;g/mL)</th><th align="left">MIC<sub>50</sub> (&#x000b5;g/mL)</th><th align="left">MIC<sub>90</sub> (&#x000b5;g/mL)</th><th align="left">Isolates (<italic>n</italic>)</th><th align="left">MIC range (&#x000b5;g/mL)</th><th align="left">MIC<sub>50</sub> (&#x000b5;g/mL)</th><th align="left">MIC<sub>90</sub> (&#x000b5;g/mL)</th></tr></thead><tbody><tr><td align="left" colspan="9">Double-blind rifaximin</td></tr><tr><td align="left">&#x000a0;Baseline (<italic>n</italic>&#x000a0;=&#x000a0;37)</td><td char="." align="char">47</td><td align="left">0.12&#x02013;&#x0003e;1024</td><td align="left">&#x0003e;1024</td><td align="left">&#x0003e;1024</td><td char="." align="char">47</td><td align="left">0.12&#x02013;&#x0003e;64</td><td align="left">&#x0003e;64</td><td align="left">&#x0003e;64</td></tr><tr><td align="left">&#x000a0;Week 2<sup>b</sup> (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">27</td><td align="left">0.12&#x02013;&#x0003e;1024</td><td align="left">&#x0003e;1024</td><td align="left">&#x0003e;1024</td><td char="." align="char">42</td><td align="left">0.12&#x02013;&#x0003e;64</td><td align="left">&#x0003e;64</td><td align="left">&#x0003e;64</td></tr><tr><td align="left">&#x000a0;Weeks 7&#x02013;10 (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td char="." align="char">2</td><td align="left">512&#x02013;&#x0003e;1024</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">2</td><td align="left">32&#x02013;&#x0003e;64</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Weeks 19&#x02013;22 (<italic>n</italic>&#x000a0;=&#x000a0;3)</td><td char="." align="char">4</td><td align="left">0.5&#x02013;&#x0003e;1024</td><td align="left">&#x0003e;1024</td><td align="left">&#x0003e;1024</td><td char="." align="char">4</td><td align="left">0.12&#x02013;&#x0003e;64</td><td align="left">&#x0003e;64</td><td align="left">&#x0003e;64</td></tr><tr><td align="left">&#x000a0;Week &#x02265;23 (<italic>n</italic>&#x000a0;=&#x000a0;30)</td><td char="." align="char">27</td><td align="left">0.12&#x02013;&#x0003e;1024</td><td align="left">256</td><td align="left">&#x0003e;1024</td><td char="." align="char">26</td><td align="left">0.03&#x02013;&#x0003e;64</td><td align="left">&#x0003e;64</td><td align="left">&#x0003e;64</td></tr><tr><td align="left" colspan="9">Double-blind placebo</td></tr><tr><td align="left">&#x000a0;Baseline (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">45</td><td align="left">0.25&#x02013;&#x0003e;1024</td><td align="left">512</td><td align="left">&#x0003e;1024</td><td char="." align="char">45</td><td align="left">0.06&#x02013;&#x0003e;64</td><td align="left">&#x0003e;64</td><td align="left">&#x0003e;64</td></tr><tr><td align="left">&#x000a0;Week 2<sup>b</sup> (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">42</td><td align="left">0.25&#x02013;&#x0003e;1024</td><td align="left">512</td><td align="left">&#x0003e;1024</td><td char="." align="char">42</td><td align="left">0.12&#x02013;&#x0003e;64</td><td align="left">&#x0003e;64</td><td align="left">&#x0003e;64</td></tr><tr><td align="left">&#x000a0;Weeks 11&#x02013;14 (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td char="." align="char">2</td><td align="left">0.5&#x02013;256</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">2</td><td align="left">0.25&#x02013;&#x0003e;64</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Weeks 15&#x02013;18 (<italic>n</italic>&#x000a0;=&#x000a0;3)</td><td char="." align="char">3</td><td align="left">128&#x02013;&#x0003e;1024</td><td align="left">&#x0003e;1024</td><td align="left">&#x0003e;1024</td><td char="." align="char">3</td><td align="left">32&#x02013;&#x0003e;64</td><td align="left">&#x0003e;64</td><td align="left">&#x0003e;64</td></tr><tr><td align="left">&#x000a0;Weeks 19&#x02013;22 (<italic>n</italic>&#x000a0;=&#x000a0;6)</td><td char="." align="char">9</td><td align="left">0.25&#x02013;&#x0003e;1024</td><td align="left">0.5</td><td align="left">&#x0003e;1024</td><td char="." align="char">9</td><td align="left">0.12&#x02013;&#x0003e;64</td><td align="left">0.12</td><td align="left">&#x0003e;64</td></tr><tr><td align="left">&#x000a0;Week &#x02265;23 (<italic>n</italic>&#x000a0;=&#x000a0;26)</td><td char="." align="char">28</td><td align="left">0.12&#x02013;&#x0003e;1024</td><td align="left">128</td><td align="left">&#x0003e;1024</td><td char="." align="char">28</td><td align="left">0.03&#x02013;&#x0003e;64</td><td align="left">16</td><td align="left">&#x0003e;64</td></tr></tbody></table><table-wrap-foot><p>
<italic>MIC</italic>&#x000a0;minimum inhibitory concentration, <italic>MIC</italic>
<sub><italic>50</italic></sub>&#x000a0;MIC at which &#x02265;50% of isolates were inhibited, <italic>MIC</italic>
<sub><italic>90</italic></sub>&#x000a0;MIC at 
which &#x02265;90% of isolates were inhibited, <italic>NA</italic>&#x000a0;not applicable</p><p>
<sup>a</sup>Follow-up period was variable; therefore, the follow-up visits were grouped into 4-week periods to determine whether there was an effect of time on antibiotic susceptibility of isolates</p><p>
<sup>b</sup>End of 2-week rifaximin or placebo treatment</p></table-wrap-foot></table-wrap>
</p><p id="Par23">No differences in susceptibility to rifaximin and rifampin were observed for <italic>C. difficile</italic> isolates identified in the double-blind rifaximin (five isolates tested) and placebo groups (nine isolates tested). <italic>C. difficile</italic> was highly susceptible to rifaximin (MIC range 0.008&#x02013;1&#x000a0;&#x000b5;g/mL) and rifampin (MIC range 0.004&#x02013;0.25&#x000a0;&#x000b5;g/mL). No <italic>C. difficile</italic> isolates were isolated beyond week 2 for the double-blind rifaximin group for rifaximin susceptibility testing.</p><p id="Par24">Susceptibility of Enterobacteriaceae isolates to rifaximin and rifampin was consistent between the double-blind rifaximin and placebo groups (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). In the double-blind rifaximin group, rifaximin MIC<sub>50</sub> values increased from baseline to week 2, then decreased to baseline levels from weeks 7 to 22 of the follow-up period. In the double-blind placebo group, rifaximin MIC<sub>50</sub> values were unchanged from baseline through the follow-up period. Rifampin MIC<sub>50</sub> values ranged between 8 and 16&#x000a0;&#x000b5;g/mL for the double-blind rifaximin group and were 16&#x000a0;&#x000b5;g/mL for all visits in the placebo group.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Susceptibility of Enterobacteriaceae to rifaximin or rifampin in the double-blind phase of the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Timepoint<sup>a</sup> (patients)</th><th align="left" colspan="4">Rifaximin</th><th align="left" colspan="4">Rifampin</th></tr><tr><th align="left">Isolates (<italic>n</italic>)</th><th align="left">MIC range (&#x000b5;g/mL)</th><th align="left">MIC<sub>50</sub> (&#x000b5;g/mL)</th><th align="left">MIC<sub>90</sub> (&#x000b5;g/mL)</th><th align="left">Isolates (<italic>n</italic>)</th><th align="left">MIC range (&#x000b5;g/mL)</th><th align="left">MIC<sub>50</sub> (&#x000b5;g/mL)</th><th align="left">MIC<sub>90</sub> (&#x000b5;g/mL)</th></tr></thead><tbody><tr><td align="left" colspan="9">Double-blind rifaximin</td></tr><tr><td align="left">&#x000a0;Baseline (<italic>n</italic>&#x000a0;=&#x000a0;37)</td><td char="." align="char">37</td><td align="left">8&#x02013;&#x0003e;128</td><td align="left">16</td><td align="left">&#x0003e;128</td><td char="." align="char">37</td><td align="left">4&#x02013;64</td><td align="left">16</td><td align="left">32</td></tr><tr><td align="left">&#x000a0;Week 2<sup>b</sup> (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">30</td><td align="left">8&#x02013;&#x0003e;128</td><td align="left">64</td><td align="left">&#x0003e;128</td><td char="." align="char">30</td><td align="left">4&#x02013;&#x0003e;128</td><td align="left">16</td><td align="left">&#x0003e;128</td></tr><tr><td align="left">&#x000a0;Weeks 7&#x02013;10 (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td char="." align="char">4</td><td align="left">8&#x02013;64</td><td align="left">16</td><td align="left">64</td><td char="." align="char">4</td><td align="left">8&#x02013;32</td><td align="left">8</td><td align="left">32</td></tr><tr><td align="left">&#x000a0;Weeks 19&#x02013;22 (<italic>n</italic>&#x000a0;=&#x000a0;3)</td><td char="." align="char">3</td><td align="left">8&#x02013;16</td><td align="left">16</td><td align="left">16</td><td char="." align="char">3</td><td align="left">4&#x02013;16</td><td align="left">8</td><td align="left">16</td></tr><tr><td align="left">&#x000a0;Week &#x02265;23 (<italic>n</italic>&#x000a0;=&#x000a0;30)</td><td char="." align="char">34</td><td align="left">8&#x02013;&#x0003e;128</td><td align="left">32</td><td align="left">64</td><td char="." align="char">34</td><td align="left">8&#x02013;&#x0003e;128</td><td align="left">16</td><td align="left">32</td></tr><tr><td align="left" colspan="9">Double-blind placebo</td></tr><tr><td align="left">&#x000a0;Baseline (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">38</td><td align="left">4&#x02013;&#x0003e;128</td><td align="left">32</td><td align="left">&#x0003e;128</td><td char="." align="char">38</td><td align="left">4&#x02013;&#x0003e;128</td><td align="left">16</td><td align="left">&#x0003e;128</td></tr><tr><td align="left">&#x000a0;Week 2<sup>b</sup> (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">41</td><td align="left">4&#x02013;&#x0003e;128</td><td align="left">32</td><td align="left">&#x0003e;128</td><td char="." align="char">41</td><td align="left">4&#x02013;&#x0003e;128</td><td align="left">16</td><td align="left">128</td></tr><tr><td align="left">&#x000a0;Weeks 11&#x02013;14 (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td char="." align="char">1</td><td align="left">8</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">1</td><td align="left">8</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Weeks 15&#x02013;18 (<italic>n</italic>&#x000a0;=&#x000a0;3)</td><td char="." align="char">2</td><td align="left">16&#x02013;32</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">2</td><td align="left">8&#x02013;16</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Weeks 19&#x02013;22 (<italic>n</italic>&#x000a0;=&#x000a0;6)</td><td char="." align="char">9</td><td align="left">4&#x02013;&#x0003e;128</td><td align="left">32</td><td align="left">&#x0003e;128</td><td char="." align="char">9</td><td align="left">1&#x02013;128</td><td align="left">16</td><td align="left">128</td></tr><tr><td align="left">&#x000a0;Week &#x02265;23 (<italic>n</italic>&#x000a0;=&#x000a0;26)</td><td char="." align="char">32</td><td align="left">4&#x02013;&#x0003e;128</td><td align="left">32</td><td align="left">&#x0003e;128</td><td char="." align="char">32</td><td align="left">8&#x02013;&#x0003e;128</td><td align="left">16</td><td align="left">32</td></tr></tbody></table><table-wrap-foot><p>
<italic>MIC</italic>&#x000a0;minimum inhibitory concentration, <italic>MIC</italic>
<sub><italic>50</italic></sub>&#x000a0;MIC at which &#x02265;50% of isolates were inhibited, <italic>MIC</italic>
<sub><italic>90</italic></sub>&#x000a0;MIC at 
which &#x02265;90% of isolates were inhibited, <italic>NA</italic>&#x000a0;not applicable</p><p>
<sup>a</sup>Follow-up period was variable; therefore, the follow-up visits were grouped into 4-week periods to determine whether there was an effect of time on antibiotic susceptibility of isolates</p><p>
<sup>b</sup>End of 2-week rifaximin or placebo treatment</p></table-wrap-foot></table-wrap>
</p><p id="Par25">The susceptibility of Enterococcaceae to rifaximin and rifampin was consistent between the double-blind rifaximin and placebo groups (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Differences were observed in the percentages of rifampin-resistant <italic>Enterococcus</italic> isolates cultured from the stools of patients receiving double-blind placebo and rifaximin at baseline (53 vs. 39%, respectively), week 2 (37 vs. 50%), and during the follow-up period (64 vs. 52%).<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Susceptibility of Enterococcaceae to rifaximin or rifampin in the double-blind phase of the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Timepoint<sup>a</sup> (patients)</th><th align="left" colspan="4">Rifaximin</th><th align="left" colspan="4">Rifampin</th></tr><tr><th align="left">Isolates (<italic>n</italic>)</th><th align="left">MIC range (&#x000b5;g/mL)</th><th align="left">MIC<sub>50</sub> (&#x000b5;g/mL)</th><th align="left">MIC<sub>90</sub> (&#x000b5;g/mL)</th><th align="left">Isolates (<italic>n</italic>)</th><th align="left">MIC range (&#x000b5;g/mL)</th><th align="left">MIC<sub>50</sub> (&#x000b5;g/mL)</th><th align="left">MIC<sub>90</sub> (&#x000b5;g/mL)</th></tr></thead><tbody><tr><td align="left">Double-blind rifaximin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Baseline (<italic>n</italic>&#x000a0;=&#x000a0;37)</td><td char="." align="char">33</td><td align="left">&#x02264;0.06&#x02013;16</td><td align="left">2</td><td align="left">16</td><td char="." align="char">33</td><td align="left">&#x02264;0.06&#x02013;16</td><td align="left">1</td><td align="left">8</td></tr><tr><td align="left">&#x000a0;Week 2<sup>b</sup> (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">20</td><td align="left">&#x02264;0.06&#x02013;32</td><td align="left">4</td><td align="left">16</td><td char="." align="char">20</td><td align="left">&#x02264;0.06&#x02013;32</td><td align="left">2</td><td align="left">16</td></tr><tr><td align="left">&#x000a0;Weeks 7&#x02013;10 (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td char="." align="char">1</td><td align="left">32</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">1</td><td align="left">8</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Weeks 19&#x02013;22 (<italic>n</italic>&#x000a0;=&#x000a0;3)</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Week &#x02265;23 (<italic>n</italic>&#x000a0;=&#x000a0;30)</td><td char="." align="char">21</td><td align="left">&#x02264;0.06&#x02013;32</td><td align="left">4</td><td align="left">32</td><td char="." align="char">21</td><td align="left">&#x02264;0.06&#x02013;32</td><td align="left">4</td><td align="left">16</td></tr><tr><td align="left">Double-blind placebo</td><td char="." align="char"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Baseline (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">19</td><td align="left">&#x02264;0.06&#x02013;32</td><td align="left">4</td><td align="left">32</td><td char="." align="char">19</td><td align="left">&#x02264;0.06&#x02013;16</td><td align="left">4</td><td align="left">16</td></tr><tr><td align="left">&#x000a0;Week 2<sup>b</sup> (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">30</td><td align="left">&#x02264;0.06&#x02013;32</td><td align="left">2</td><td align="left">16</td><td char="." align="char">30</td><td align="left">&#x02264;0.06&#x02013;32</td><td align="left">2</td><td align="left">16</td></tr><tr><td align="left">&#x000a0;Weeks 11&#x02013;14 (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Weeks 15&#x02013;18 (<italic>n</italic>&#x000a0;=&#x000a0;3)</td><td char="." align="char">1</td><td align="left">2</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">1</td><td align="left">1</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Weeks 19&#x02013;22 (<italic>n</italic>&#x000a0;=&#x000a0;6)</td><td char="." align="char">7</td><td align="left">0.5&#x02013;16</td><td align="left">4</td><td align="left">16</td><td char="." align="char">7</td><td align="left">0.15&#x02013;16</td><td align="left">4</td><td align="left">16</td></tr><tr><td align="left">&#x000a0;Week &#x02265;23 (<italic>n</italic>&#x000a0;=&#x000a0;26)</td><td char="." align="char">17</td><td align="left">&#x02264;0.06&#x02013;32</td><td align="left">16</td><td align="left">32</td><td char="." align="char">17</td><td align="left">&#x02264;0.06&#x02013;32</td><td align="left">8</td><td align="left">32</td></tr></tbody></table><table-wrap-foot><p>
<italic>MIC</italic>&#x000a0;minimum inhibitory concentration, <italic>MIC</italic>
<sub><italic>50</italic></sub>&#x000a0;MIC at which &#x02265;50% of isolates were inhibited, <italic>MIC</italic>
<sub><italic>90</italic></sub>&#x000a0;MIC at 
which &#x02265;90% of isolates were inhibited, <italic>NA</italic>&#x000a0;not applicable</p><p>
<sup>a</sup>Follow-up period was variable; therefore, the follow-up visits were grouped into 4-week periods to determine whether there was an effect of time on antibiotic susceptibility of isolates</p><p>
<sup>b</sup>End of 2-week rifaximin treatment</p></table-wrap-foot></table-wrap>
</p><p id="Par26">A total of three Pseudomonadaceae isolates were identified and evaluated for susceptibility to rifaximin and rifampin. The one isolate from the double-blind rifaximin group had rifaximin and rifampin MICs of 16 and 32&#x000a0;&#x000b5;g/mL, respectively. The two isolates from the placebo group had a baseline rifaximin and rifampin MIC of 16&#x000a0;&#x000b5;g/mL and had rifaximin and rifampin MICs of 4 and 8&#x000a0;&#x000b5;g/mL, respectively, during the follow-up period (weeks 19&#x02013;22).</p><p id="Par27">Staphylococcal isolates remained susceptible to rifaximin and rifampin at all visits in the double-blind placebo group. In the double-blind rifaximin group, the rifaximin MIC<sub>50</sub> increased from baseline to week 2 (&#x02264;0.06&#x02013;32&#x000a0;&#x000b5;g/mL, respectively), but the five isolates evaluated in the follow-up period had rifaximin MICs&#x000a0;&#x02264;&#x000a0;0.06&#x000a0;&#x000b5;g/mL (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). At baseline, 11 and 13% of staphylococcal isolates in the rifaximin and placebo groups, respectively, were rifampin resistant (MIC&#x000a0;&#x02265;&#x000a0;4&#x000a0;&#x000b5;g/mL); at week 2, 70% of staphylococcal isolates in the rifaximin group were rifampin resistant. However, repeat treatment with rifaximin did not have an apparent effect on the long-term susceptibility of staphylococcal isolates to rifampin, as isolates recovered sensitivity to rifampin in the follow-up period (&#x02264;0.06&#x000a0;&#x000b5;g/mL).<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Susceptibility of Staphylococcaceae to rifaximin or rifampin in the double-blind phase of the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Timepoint<sup>a</sup> (patients)</th><th align="left" colspan="4">Rifaximin</th><th align="left" colspan="4">Rifampin</th></tr><tr><th align="left">Isolates (<italic>n</italic>)</th><th align="left">MIC range (&#x000b5;g/mL)</th><th align="left">MIC<sub>50</sub> (&#x000b5;g/mL)</th><th align="left">MIC<sub>90</sub> (&#x000b5;g/mL)</th><th align="left">Isolates (<italic>n</italic>)</th><th align="left">MIC range (&#x000b5;g/mL)</th><th align="left">MIC<sub>50</sub> (&#x000b5;g/mL)</th><th align="left">MIC<sub>90</sub> (&#x000b5;g/mL)</th></tr></thead><tbody><tr><td align="left">Double-blind rifaximin</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Baseline (<italic>n</italic>&#x000a0;=&#x000a0;37)</td><td char="." align="char">9</td><td align="left">&#x02264;0.06&#x02013;64</td><td align="left">&#x02264;0.06</td><td align="left">64</td><td char="." align="char">9</td><td align="left">&#x02264;0.06&#x02013;&#x0003e;128</td><td align="left">&#x02264;0.06</td><td align="left">&#x0003e;128</td></tr><tr><td align="left">&#x000a0;Week 2<sup>b</sup> (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">10</td><td align="left">&#x02264;0.06&#x02013;64</td><td align="left">32</td><td align="left">64</td><td char="." align="char">10</td><td align="left">&#x02264;0.06&#x02013;&#x0003e;128</td><td align="left">&#x0003e;128</td><td align="left">&#x0003e;128</td></tr><tr><td align="left">&#x000a0;Weeks 7&#x02013;10 (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Weeks 19&#x02013;22 (<italic>n</italic>&#x000a0;=&#x000a0;3)</td><td char="." align="char">2</td><td align="left">&#x02264;0.06</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">2</td><td align="left">&#x02264;0.06</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Week &#x02265;23 (<italic>n</italic>&#x000a0;=&#x000a0;30)</td><td char="." align="char">3</td><td align="left">&#x02264;0.06</td><td align="left">&#x02264;0.06</td><td align="left">&#x02264;0.06</td><td char="." align="char">3</td><td align="left">&#x02264;0.06</td><td align="left">&#x02264;0.06</td><td align="left">&#x02264;0.06</td></tr><tr><td align="left">Double-blind placebo</td><td char="." align="char"/><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Baseline (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">8</td><td align="left">&#x02264;0.06&#x02013;32</td><td align="left">&#x02264;0.06</td><td align="left">32</td><td char="." align="char">8</td><td align="left">&#x02264;0.06&#x02013;&#x0003e;128</td><td align="left">&#x02264;0.06</td><td align="left">&#x0003e;128</td></tr><tr><td align="left">&#x000a0;Week 2<sup>b</sup> (<italic>n</italic>&#x000a0;=&#x000a0;36)</td><td char="." align="char">7</td><td align="left">&#x02264;0.06&#x02013;64</td><td align="left">&#x02264;0.06</td><td align="left">64</td><td char="." align="char">7</td><td align="left">&#x02264;0.06&#x02013;&#x0003e;128</td><td align="left">&#x02264;0.06</td><td align="left">&#x0003e;128</td></tr><tr><td align="left">&#x000a0;Weeks 11&#x02013;14 (<italic>n</italic>&#x000a0;=&#x000a0;1)</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Weeks 15&#x02013;18 (<italic>n</italic>&#x000a0;=&#x000a0;3)</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Weeks 19&#x02013;22 (<italic>n</italic>&#x000a0;=&#x000a0;6)</td><td char="." align="char">1</td><td align="left">&#x02264;0.06</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">1</td><td align="left">&#x02264;0.06</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Week &#x02265;23 (<italic>n</italic>&#x000a0;=&#x000a0;26)</td><td char="." align="char">6</td><td align="left">&#x02264;0.06</td><td align="left">&#x02264;0.06</td><td align="left">&#x02264;0.06</td><td char="." align="char">6</td><td align="left">&#x02264;0.06</td><td align="left">&#x02264;0.06</td><td align="left">&#x02264;0.06</td></tr></tbody></table><table-wrap-foot><p>
<italic>MIC</italic>&#x000a0;minimum inhibitory concentration, <italic>MIC</italic>
<sub><italic>50</italic></sub>&#x000a0;MIC at which &#x02265;50% of isolates were inhibited, <italic>MIC</italic>
<sub><italic>90</italic></sub>&#x000a0;MIC at 
which &#x02265;90% of isolates were inhibited, <italic>NA</italic>&#x000a0;not applicable</p><p>
<sup>a</sup>Follow-up period was variable; therefore, the follow-up visits were grouped into 4-week periods to determine whether there was an effect of time on antibiotic susceptibility of isolates</p><p>
<sup>b</sup>End of 2-week rifaximin treatment</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec12"><title>Other Antibiotic Susceptibility</title><p id="Par28">In the open-label phase, there was no apparent cross-resistance of Bacteroidaceae (Table S5), Enterobacteriaceae (Table S6), and Enterococcaceae (Table S7) to nonrifamycin antibiotics following exposure to rifaximin. The small number of Clostridiaceae, Pseudomonadaceae, and Staphylococcaceae isolates available limited MIC<sub>50</sub> analyses at the time points assessed with antibiotics tested.</p><p id="Par29">In the double-blind phase, there was no apparent cross-resistance of Bacteroidaceae (Table S8), Enterobacteriaceae (Table S9), and Enterococcaceae (Table S10) to nonrifamycin antibiotics following rifaximin exposure. The small number of Clostridiaceae, Pseudomonadaceae, and Staphylococcaceae isolates available limited MIC<sub>50</sub> analyses at the time points assessed with the antibiotics tested.</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par30">In the current study, short-term repeat treatment with rifaximin in patients with IBS-D was not associated with clinically meaningful resistance to rifaximin, rifampin, and nonrifamycin antibiotics tested in the long term. These findings support previous reports about rifaximin treatment of patients with hepatic encephalopathy or travelers&#x02019; diarrhea, suggesting that the potential for development of cross-resistance to nonrifamycin antibiotics following treatment with rifaximin is low [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par31">Overall, bacterial isolates were susceptible to rifaximin and rifampin during the open-label and double-blind phases of the study. Increases in the MIC<sub>50</sub> or the MIC<sub>90</sub> of rifaximin against <italic>Bacteroides</italic> were within baseline MIC ranges during both the open-label and the double-blind phases of the study and within the MIC ranges previously reported in the literature [<xref ref-type="bibr" rid="CR35">35</xref>]. The MIC<sub>50</sub> of rifaximin with Enterobacteriaceae increased at week 2 in both the open-label and the double-blind phases of this study but recovered to baseline levels in the follow-up period; this observation is consistent with the rapid elimination of rifaximin-resistant bacteria, particularly aerobes, from the stool [<xref ref-type="bibr" rid="CR26">26</xref>]. Transient increases in rifaximin and rifampin MIC<sub>50</sub> values for staphylococcal isolates were observed after treatment with open-label rifaximin (week 2) and after repeat treatment with double-blind rifaximin (week 2); however, MIC values for rifaximin and rifampin returned to baseline levels as the duration of time post-rifaximin exposure increased (week&#x000a0;&#x02265;&#x000a0;23). The transient increases observed in the short term do not appear to be clinically harmful. Yeast growth can occur following treatment with some antibiotics [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]; however, the small number of yeast isolates identified supports a previous finding that rifaximin does not create an environment favorable to yeast growth [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par32">A previous study has shown that some patients with IBS may be predisposed to infection with <italic>C. difficile</italic>, although isolates from these patients were susceptible to the antibiotics tested [<xref ref-type="bibr" rid="CR38">38</xref>]. One limitation of the current study was the lack of consistency in antimicrobial susceptibility testing for bacterial families with a small number of isolates identified (i.e., Clostridiaceae, Pseudomonadaceae). The human gut microbiome is thought to contain at least 1200 different microorganisms; thus, an additional limitation of this study was the limited number of bacterial species examined for resistance relative to the quantity and diversity of microbes in the human gut microbiome [<xref ref-type="bibr" rid="CR39">39</xref>]. Finally, the use of fecal samples, while noninvasive, may not be entirely representative of the composition and, possibly, activity of the gut microbiota in vivo [<xref ref-type="bibr" rid="CR40">40</xref>]. Indeed, the bacterial composition of fecal and colonic mucosa differed significantly in both healthy individuals (<italic>P</italic>&#x000a0;=&#x000a0;0.0001) and patients with IBS-D (<italic>P</italic>&#x000a0;=&#x000a0;0.001).</p><p id="Par33">The large number of patients with prospectively collected stool samples available for microbial susceptibility testing strengthens study results. Potential limitations of the study include the small number of isolates collected from some bacterial families, thus limiting potential robustness of the susceptibility testing, uncertainty as to whether this patient sampling was representative of a general population with IBS-D, and the lack of evaluation of the potential relationship between susceptibility profiles and clinical response observed in Trial 3.</p><p id="Par34">In conclusion, because of the potential for chronicity of IBS-D symptoms, patients may require repeat treatment with rifaximin for the management of symptoms [<xref ref-type="bibr" rid="CR2">2</xref>]. Based on the results of this prospective study, there is no evidence of long-term clinically relevant antibiotic resistance with repeated courses of rifaximin for the treatment of IBS-D.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec14"><p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10620_2017_4598_MOESM1_ESM.docx"><caption><p>Supplementary material 1 (DOCX 39&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p>R. A. Wolf: Former employee of Salix Pharmaceuticals, 400 Somerset Corporate Blvd., Bridgewater, NJ 08807, USA.</p></fn><fn><p>Guarantor of the article: Mark Pimentel.</p></fn><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1007/s10620-017-4598-7) contains supplementary material, which is available to authorized users.</p></fn><fn><p>An erratum to this article is available at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10620-017-4729-1">https://doi.org/10.1007/s10620-017-4729-1</ext-link>.</p></fn></fn-group><ack><p>Technical editorial assistance was provided, under the direction of the authors, by Mary Beth Moncrief, Ph.D., and Sophie Bolick, Ph.D., Synchrony Medical Communications, LLC, West Chester, PA, USA. Funding for this support was provided by Salix Pharmaceuticals, Bridgewater, NJ, USA.</p></ack><notes notes-type="author-contribution"><title>Author's contributions</title><p>Dr. Pimentel contributed to the study design, participated in the conduct of the study, analyzed data, and critically reviewed and edited the manuscript. Dr. Cash contributed to the study design, analyzed data, and critically reviewed and edited the manuscript. Dr. Lembo contributed to the study design, participated in the conduct of the study, analyzed data, and critically reviewed and edited the manuscript. Dr. Schoenfeld contributed to the study design, participated in the conduct of the study, analyzed data, and critically reviewed and edited the manuscript. Drs. Wolf and Israel analyzed data and critically reviewed and edited the manuscript. All of the authors approved the final version of the manuscript, including the authorship list.</p></notes><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar2"><title>Conflict of interest</title><p id="Par36">M. Pimentel reports serving as a consultant for and receiving research funding from Salix Pharmaceuticals. In addition, Cedars-Sinai Medical Center has a licensing agreement with Salix Pharmaceuticals. B.D. Cash reports serving as a speaker, consultant, and an advisory board member for Salix Pharmaceuticals. A. Lembo reports serving as a consultant and an advisory board member for Salix Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Allergan plc, Ardelyx, and Valeant Pharmaceuticals. R.A. Wolf is a former employee of Salix Pharmaceuticals. R.J. Israel is an employee of Salix Pharmaceuticals or its affiliates. P. Schoenfeld reports serving as a consultant and advisory board member for Salix Pharmaceuticals, Ironwood Pharmaceuticals, Allergan, and Commonwealth Laboratories, a division of Valeant Pharmaceuticals North America LLC.</p></sec><sec id="FPar3"><title>Ethical standards</title><p id="Par37">All procedures performed in the study were in accordance with the International Standard of Good Clinical Practice procedures and with the principles of the Declaration of Helsinki (1964) and relevant amendments. The protocol was approved by all institutional review boards and ethics committees at participating sites.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacy</surname><given-names>BE</given-names></name><name><surname>Mearin</surname><given-names>F</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Bowel disorders</article-title><source>Gastroenterology</source><year>2016</year><volume>150</volume><fpage>1393</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.02.031</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Kurlander</surname><given-names>J</given-names></name><name><surname>Eswaran</surname><given-names>S</given-names></name></person-group><article-title>Irritable bowel syndrome: a clinical review</article-title><source>JAMA</source><year>2015</year><volume>313</volume><fpage>949</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.0954</pub-id><pub-id pub-id-type="pmid">25734736</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>IM</given-names></name><name><surname>Chang</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Sartor</surname><given-names>RB</given-names></name><name><surname>Ringel</surname><given-names>Y</given-names></name></person-group><article-title>Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome</article-title><source>Gut Pathog</source><year>2010</year><volume>2</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/1757-4749-2-19</pub-id><pub-id pub-id-type="pmid">21143915</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shankar</surname><given-names>V</given-names></name><name><surname>Homer</surname><given-names>D</given-names></name><name><surname>Rigsbee</surname><given-names>L</given-names></name><etal/></person-group><article-title>The networks of human gut microbe-metabolite associations are different between health and irritable bowel syndrome</article-title><source>ISME J</source><year>2015</year><volume>9</volume><fpage>1899</fpage><lpage>1903</lpage><pub-id pub-id-type="doi">10.1038/ismej.2014.258</pub-id><pub-id pub-id-type="pmid">25635640</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigsbee</surname><given-names>L</given-names></name><name><surname>Agans</surname><given-names>R</given-names></name><name><surname>Shankar</surname><given-names>V</given-names></name><etal/></person-group><article-title>Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome</article-title><source>Am J Gastroenterol</source><year>2012</year><volume>107</volume><fpage>1740</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1038/ajg.2012.287</pub-id><pub-id pub-id-type="pmid">22986438</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajilic-Stojanovic</surname><given-names>M</given-names></name><name><surname>Biagi</surname><given-names>E</given-names></name><name><surname>Heilig</surname><given-names>HG</given-names></name><etal/></person-group><article-title>Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome</article-title><source>Gastroenterology</source><year>2011</year><volume>141</volume><fpage>1792</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.07.043</pub-id><pub-id pub-id-type="pmid">21820992</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>AC</given-names></name><name><surname>Moayyedi</surname><given-names>P</given-names></name><name><surname>Lacy</surname><given-names>BE</given-names></name><etal/></person-group><article-title>American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation</article-title><source>Am J Gastroenterol</source><year>2014</year><volume>109</volume><fpage>S2</fpage><lpage>S26</lpage><pub-id pub-id-type="doi">10.1038/ajg.2014.187</pub-id><pub-id pub-id-type="pmid">25091148</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel</surname><given-names>M</given-names></name><name><surname>Chow</surname><given-names>EJ</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name></person-group><article-title>Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study</article-title><source>Am J Gastroenterol</source><year>2003</year><volume>98</volume><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2003.07946.x</pub-id><pub-id pub-id-type="pmid">12591062</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel</surname><given-names>M</given-names></name><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Chow</surname><given-names>EJ</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name></person-group><article-title>Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study</article-title><source>Dig Dis Sci</source><year>2006</year><volume>51</volume><fpage>1297</fpage><lpage>1301</lpage><pub-id pub-id-type="doi">10.1007/s10620-006-9104-6</pub-id><pub-id pub-id-type="pmid">16832617</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basseri</surname><given-names>RJ</given-names></name><name><surname>Weitsman</surname><given-names>S</given-names></name><name><surname>Barlow</surname><given-names>GM</given-names></name><name><surname>Pimentel</surname><given-names>M</given-names></name></person-group><article-title>Antibiotics for the treatment of irritable bowel syndrome</article-title><source>Gastroenterol Hepatol</source><year>2011</year><volume>7</volume><fpage>455</fpage><lpage>493</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cash</surname><given-names>BD</given-names></name></person-group><article-title>Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome</article-title><source>Curr Med Res Opin</source><year>2014</year><volume>30</volume><fpage>1405</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1185/03007995.2014.908278</pub-id><pub-id pub-id-type="pmid">24666019</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blondeau</surname><given-names>JM</given-names></name></person-group><article-title>What have we learned about antimicrobial use and the risks for <italic>Clostridium difficile</italic>-associated diarrhoea?</article-title><source>J Antimicrob Chemother</source><year>2009</year><volume>63</volume><fpage>238</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn477</pub-id><pub-id pub-id-type="pmid">19028718</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>ZD</given-names></name><name><surname>DuPont</surname><given-names>HL</given-names></name></person-group><article-title>Rifaximin: in vitro and in vivo antibacterial activity&#x02014;a review</article-title><source>Chemotherapy</source><year>2005</year><volume>51</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1159/000081991</pub-id><pub-id pub-id-type="pmid">15855749</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchese</surname><given-names>A</given-names></name><name><surname>Salerno</surname><given-names>A</given-names></name><name><surname>Pesce</surname><given-names>A</given-names></name><name><surname>Debbia</surname><given-names>EA</given-names></name><name><surname>Schito</surname><given-names>GC</given-names></name></person-group><article-title>In vitro activity of rifaximin, metronidazole and vancomycin against <italic>Clostridium difficile</italic> and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species</article-title><source>Chemotherapy</source><year>2000</year><volume>46</volume><fpage>253</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1159/000007297</pub-id><pub-id pub-id-type="pmid">10859431</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillis</surname><given-names>JC</given-names></name><name><surname>Brogden</surname><given-names>RN</given-names></name></person-group><article-title>Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria</article-title><source>Drugs</source><year>1995</year><volume>49</volume><fpage>467</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.2165/00003495-199549030-00009</pub-id><pub-id pub-id-type="pmid">7774516</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Xifaxan<sup>&#x000ae;</sup> (rifaximin) tablets, for oral use [package insert]. Bridgewater, NJ: Salix Pharmaceuticals; 2015.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel</surname><given-names>M</given-names></name><name><surname>Lembo</surname><given-names>A</given-names></name><name><surname>Chey</surname><given-names>WD</given-names></name><etal/></person-group><article-title>Rifaximin therapy for patients with irritable bowel syndrome without constipation</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1004409</pub-id><pub-id pub-id-type="pmid">21208106</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyrat</surname><given-names>P</given-names></name><name><surname>Safroneeva</surname><given-names>E</given-names></name><name><surname>Schoepfer</surname><given-names>AM</given-names></name></person-group><article-title>Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months</article-title><source>Aliment Pharmacol Ther</source><year>2012</year><volume>36</volume><fpage>1084</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1111/apt.12087</pub-id><pub-id pub-id-type="pmid">23066911</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Mirocha</surname><given-names>J</given-names></name><name><surname>Kane</surname><given-names>SV</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name></person-group><article-title>The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial</article-title><source>Ann Intern Med</source><year>2006</year><volume>145</volume><fpage>557</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-145-8-200610170-00004</pub-id><pub-id pub-id-type="pmid">17043337</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel</surname><given-names>M</given-names></name><name><surname>Morales</surname><given-names>W</given-names></name><name><surname>Chua</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects</article-title><source>Dig Dis Sci</source><year>2011</year><volume>56</volume><fpage>2067</fpage><lpage>2072</lpage><pub-id pub-id-type="doi">10.1007/s10620-011-1728-5</pub-id><pub-id pub-id-type="pmid">21559740</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lembo</surname><given-names>A</given-names></name><name><surname>Pimentel</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome</article-title><source>Gastroenterology</source><year>2016</year><volume>151</volume><fpage>1113</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.08.003</pub-id><pub-id pub-id-type="pmid">27528177</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenfeld</surname><given-names>P</given-names></name><name><surname>Pimentel</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials</article-title><source>Aliment Pharmacol Ther</source><year>2014</year><volume>39</volume><fpage>1161</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1111/apt.12735</pub-id><pub-id pub-id-type="pmid">24697851</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>DN</given-names></name><name><surname>McKenzie</surname><given-names>R</given-names></name><name><surname>Durbin</surname><given-names>A</given-names></name><name><surname>Carpenter</surname><given-names>C</given-names></name><name><surname>Haake</surname><given-names>R</given-names></name><name><surname>Bourgeois</surname><given-names>AL</given-names></name></person-group><article-title>Systemic pharmacokinetics of rifaximin in volunteers with shigellosis</article-title><source>Antimicrob Agents Chemother</source><year>2008</year><volume>52</volume><fpage>1179</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1128/AAC.01108-07</pub-id><pub-id pub-id-type="pmid">18086855</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Descombe</surname><given-names>JJ</given-names></name><name><surname>Dubourg</surname><given-names>D</given-names></name><name><surname>Picard</surname><given-names>M</given-names></name><name><surname>Palazzini</surname><given-names>E</given-names></name></person-group><article-title>Pharmacokinetic study of rifaximin after oral administration in healthy volunteers</article-title><source>Int J Clin Pharmacol Res</source><year>1994</year><volume>14</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">7836025</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kothary</surname><given-names>V</given-names></name><name><surname>Scherl</surname><given-names>EJ</given-names></name><name><surname>Bosworth</surname><given-names>B</given-names></name><etal/></person-group><article-title>Rifaximin resistance in <italic>Escherichia coli</italic> associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in <italic>rpoB</italic>, and activity of phe-arg-b-naphthylamide-inhibitable efflux pumps</article-title><source>Antimicrob Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>811</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1128/AAC.02163-12</pub-id><pub-id pub-id-type="pmid">23183443</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Leo</surname><given-names>C</given-names></name><name><surname>Eftimiadi</surname><given-names>C</given-names></name><name><surname>Schito</surname><given-names>GC</given-names></name></person-group><article-title>Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin</article-title><source>Drugs Exp Clin Res</source><year>1986</year><volume>12</volume><fpage>979</fpage><lpage>981</lpage><pub-id pub-id-type="pmid">3569008</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brigidi</surname><given-names>P</given-names></name><name><surname>Swennen</surname><given-names>E</given-names></name><name><surname>Rizzello</surname><given-names>F</given-names></name><name><surname>Bozzolasco</surname><given-names>M</given-names></name><name><surname>Matteuzzi</surname><given-names>D</given-names></name></person-group><article-title>Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis</article-title><source>J Chemother</source><year>2002</year><volume>14</volume><fpage>290</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1179/joc.2002.14.3.290</pub-id><pub-id pub-id-type="pmid">12120885</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>J</given-names></name><name><surname>Mensa</surname><given-names>L</given-names></name><name><surname>Pons</surname><given-names>MJ</given-names></name><name><surname>Vila</surname><given-names>J</given-names></name><name><surname>Gascon</surname><given-names>J</given-names></name></person-group><article-title>Development of <italic>Escherichia coli</italic> rifaximin-resistant mutants: frequency of selection and stability</article-title><source>J Antimicrob Chemother</source><year>2008</year><volume>61</volume><fpage>1016</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn078</pub-id><pub-id pub-id-type="pmid">18325895</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement, CLSI document M100-S24. Wayne, PA; 2014.</mixed-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullen</surname><given-names>KD</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name><name><surname>Bass</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy</article-title><source>Clin Gastroenterol Hepatol</source><year>2014</year><volume>12</volume><fpage>1390</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2013.12.021</pub-id><pub-id pub-id-type="pmid">24365449</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bass</surname><given-names>NM</given-names></name><name><surname>Mullen</surname><given-names>KD</given-names></name><name><surname>Sanyal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Rifaximin treatment in hepatic encephalopathy</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>1071</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0907893</pub-id><pub-id pub-id-type="pmid">20335583</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajaj</surname><given-names>JS</given-names></name><name><surname>Barrett</surname><given-names>AC</given-names></name><name><surname>Bortey</surname><given-names>E</given-names></name><name><surname>Paterson</surname><given-names>C</given-names></name><name><surname>Forbes</surname><given-names>WP</given-names></name></person-group><article-title>Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis</article-title><source>Aliment Pharmacol Ther</source><year>2015</year><volume>41</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/apt.12993</pub-id><pub-id pub-id-type="pmid">25339518</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuPont</surname><given-names>HL</given-names></name><name><surname>Jiang</surname><given-names>ZD</given-names></name><name><surname>Okhuysen</surname><given-names>PC</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers&#x02019; diarrhea</article-title><source>Ann Intern Med</source><year>2005</year><volume>142</volume><fpage>805</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-142-10-200505170-00005</pub-id><pub-id pub-id-type="pmid">15897530</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuPont</surname><given-names>HL</given-names></name><name><surname>Jiang</surname><given-names>ZD</given-names></name></person-group><article-title>Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and <italic>Enterococci</italic></article-title><source>Clin Microbiol Infect</source><year>2004</year><volume>10</volume><fpage>1009</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2004.00997.x</pub-id><pub-id pub-id-type="pmid">15522005</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finegold</surname><given-names>SM</given-names></name><name><surname>Molitoris</surname><given-names>D</given-names></name><name><surname>Vaisanen</surname><given-names>ML</given-names></name></person-group><article-title>Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1128/AAC.00441-08</pub-id><pub-id pub-id-type="pmid">18955526</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakata</surname><given-names>H</given-names></name><name><surname>Fujita</surname><given-names>K</given-names></name><name><surname>Yoshioka</surname><given-names>H</given-names></name></person-group><article-title>The effect of antimicrobial agents on fecal flora of children</article-title><source>Antimicrob Agents Chemother</source><year>1986</year><volume>29</volume><fpage>225</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1128/AAC.29.2.225</pub-id><pub-id pub-id-type="pmid">3087275</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samonis</surname><given-names>G</given-names></name><name><surname>Gikas</surname><given-names>A</given-names></name><name><surname>Anaissie</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans</article-title><source>Antimicrob Agents Chemother</source><year>1993</year><volume>37</volume><fpage>51</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.1.51</pub-id><pub-id pub-id-type="pmid">8431017</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clayton</surname><given-names>EM</given-names></name><name><surname>Rea</surname><given-names>MC</given-names></name><name><surname>Shanahan</surname><given-names>F</given-names></name><etal/></person-group><article-title>Carriage of Clostridium difficile in outpatients with irritable bowel syndrome</article-title><source>J Med Microbiol</source><year>2012</year><volume>61</volume><fpage>1290</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.040568-0</pub-id><pub-id pub-id-type="pmid">22580916</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajilic-Stojanovic</surname><given-names>M</given-names></name><name><surname>Smidt</surname><given-names>H</given-names></name><name><surname>de Vos</surname><given-names>WM</given-names></name></person-group><article-title>Diversity of the human gastrointestinal tract microbiota revisited</article-title><source>Environ Microbiol</source><year>2007</year><volume>9</volume><fpage>2125</fpage><lpage>2136</lpage><pub-id pub-id-type="doi">10.1111/j.1462-2920.2007.01369.x</pub-id><pub-id pub-id-type="pmid">17686012</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>IM</given-names></name><name><surname>Ringel-Kulka</surname><given-names>T</given-names></name><name><surname>Keku</surname><given-names>TO</given-names></name><etal/></person-group><article-title>Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2011</year><volume>301</volume><fpage>G799</fpage><lpage>G807</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00154.2011</pub-id><pub-id pub-id-type="pmid">21737778</pub-id></element-citation></ref></ref-list></back></article>